Gilead Sciences (GILD) Declines More Than Market: Some Information for Investors

Gilead Sciences declined 1.21% on September 30, 2026, underperforming the S&P 500's 0.25% loss. The HIV and hepatitis C drugmaker faces headwinds with projected quarterly EPS down 12.96% year-over-year, though revenue is expected to rise slightly by 0.3%. The company holds a Zacks Rank #3 (Hold) rating with consensus EPS estimates revised 2.2% lower over the past month.